GW Pharmaceuticals (Nasdaq: GWPH) tremendous 700% one year run is showing no signs of slowing down. The drug developer, often lumped in with marijuana stocks due to its focus on the cannabinoid system, received an FDA fast track designation for its orphan drug Epidiolex. This drug is hoping to treat Dravet and Lennox- Gastaut syndromes, both are rare forms of pediatric epilepsy and have a significant unmet need for treatments.

Epidiolex as a wholly owned drug has significant potential for GW and could cross $500 million in global peak sales, easily supplanting its current approved drug Sativex as the company's flagship product.

In this episode of Market Checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss the recent regulatory good news, the market potential for Epidiolex and why Fools should be watching this stock closely.


David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.